Agennix(德國)

Agennix

美國Agennixwww.agennix.comGPCBiotechAG(NASDAQ:GPCB)和Agennix于2009年2月18號簽訂商業(yè)合并協(xié)議AgennixAGisabiopharmaceuticalcompanyresultingfromthecombinationofGPCBiotechAGandAgennixIncorporatedinNovember2009.Weseektoha veameaningfulimpactonthelengthandqualityoflivesofcancerpatientsinareasofmajorunmetmedicalneedbydeveloping,andobtainingapprovalfor,noveloncologytherapies.Ourmostadvancedprogramistalactoferrin,anoraltargetedtherapythatisinPhase3clinicaltrialsinnon-smallcelllungcancer.Additionalclinicaltrialswithtalactoferrinincancerindicationsareplanned,includingkidneycancer,forwhichPhase2dataareavailable.OurotherclinicaldevelopmentprogramsincludeRGB-286638,amulti-targetedkinaseinhibitorinPhase1testing;theoralplatinum-basedcompoundsatraplatin;andatopicalgelformoftalactoferrinforwoundhealing.Weareatransatlanticcompanywithsitesin